Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
On February 12, 2025, Dr. Reddy’s Laboratories received an order from the GST Authority concerning a tax demand, including interest and penalties, related to irregular Cenvat Credit of Service Tax. The order, dated February 7, 2025, imposes a penalty of Rs. 1,80,82,606, but the company has assessed that this will not materially impact its financials or operations. Dr. Reddy’s is considering filing an appeal with the appellate authority regarding this order.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical company based in Hyderabad, Telangana, India. The company primarily focuses on the development, manufacture, and marketing of pharmaceutical products, including generic medications, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) drugs. It operates in markets across India and internationally, with a significant presence on stock exchanges such as the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
YTD Price Performance: -11.87%
Average Trading Volume: 1,702,624
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.75B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
